Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H35N8O6P.C4H6O4 |
Molecular Weight | 644.6144 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC(O)=O.CCOC(=O)[C@H](C)NP(=O)(COCCN1C=NC2=C(NC3CC3)N=C(N)N=C12)N[C@@H](C)C(=O)OCC
InChI
InChIKey=XLBDQSJWTNREFA-IODNYQNNSA-N
InChI=1S/C21H35N8O6P.C4H6O4/c1-5-34-19(30)13(3)27-36(32,28-14(4)20(31)35-6-2)12-33-10-9-29-11-23-16-17(24-15-7-8-15)25-21(22)26-18(16)29;5-3(6)1-2-4(7)8/h11,13-15H,5-10,12H2,1-4H3,(H2,27,28,32)(H3,22,24,25,26);1-2H2,(H,5,6)(H,7,8)/t13-,14-;/m0./s1
Rabacfosadine was approved in 2017 under the brand name Tanovea-CA1 for the treatment of canine lymphoma. In addition, this drug has demonstrated effectiveness against non-Hodgkin's lymphoma in dogs, as well as canine cutaneous T-cell lymphoma, and relapsed canine B-cell lymphoma. Rabacfosadine a prodrug, which is hydrolyzed intracellularly to the metabolites, 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP) and 9-(2-phosphonylmethoxyethyl) guanine (PMEG). PMEG is then converted to its active phosphorylated form, which is a chain-terminating inhibitor of the replicative deoxyribonucleic acid (DNA) polymerases.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL613496 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8669893 |
1.7 µM [EC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=407d42d7-2e23-4e90-aff0-b8b05d226e4b
Curator's Comment: in dogs
Administer TANOVEA-CA1 at 1 mg/kg body weight as a 30-minute intravenous infusion, once every three weeks, for up to five doses. Stepwise dose reductions to 0.8 mg/kg and 0.66 mg/kg or dose delays may be used to manage adverse reactions.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C274
Created by
admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3L28LG748I
Created by
admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
|
PRIMARY | |||
|
73425536
Created by
admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
|
PRIMARY | |||
|
300000017693
Created by
admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
|
PRIMARY | |||
|
1431856-99-3
Created by
admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
|
PRIMARY | |||
|
AB-138
Created by
admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
|
PRIMARY | |||
|
2003594
Created by
admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
|
PRIMARY | |||
|
3L28LG748I
Created by
admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
|
PRIMARY | |||
|
C152135
Created by
admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL1823518
Created by
admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD